Prof Georgina Long and Prof Richard Scolyer, cycled from Albury to Wagga on Day 1 of Riverina Melanoma Ride.
Melanoma March 2022 is aiming to raise $1 million for a world-first clinical trial of a Personalised Immunotherapy Platform which could transform melanoma treatment.
A landmark report provides status of melanoma in Australia, and the the roadmap to achieve zero deaths from melanoma this decade.
In what is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy, a new study has revealed that drug treatment before surgery is effective in preventing deadly spread of the disease.
MIA has joined Sydney Health Partners, with a shared focus on more rapidly translating research evidence into patient benefit.
Jana Pittman and Melinda Gainsford-Taylor back our Game On Mole campaign, in support of their much loved coach.
The 'Distinguished Alumni Award' from University of Tasmania honours the exceptional impact of his work around the world.
The 'Outstanding Research Award' recognises their life-saving discoveries transforming melanoma patient care.
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.
Drug therapy looks set to become the standard treatment for high-risk early stage melanoma patients.